iTeos Therapeutics, Inc.
iteostherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops antibody and small-molecule cancer drug candidates for people with cancer, particularly solid tumors.
10-K for FY2024, filed Mar 5, 2025
How Did They Make Money?
Under its GSK collaboration, iTeos received an upfront payment for rights to develop, manufacture and commercialize belrestotug, and was eligible for payments tied to development and commercial milestones. It also earned payments for clinical-study, clinical-supply manufacturing and know-how-transfer work as the work progressed.
10-K for FY2024, filed Mar 5, 2025Maximize the value of our product candidates and pipeline by selectively entering into strategic collaborations. We seek to establish…View ↗
The transaction price is being recognized as revenue over time as the costs to complete the Phase 1 study, perform interim clinical supply…View ↗
At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of…View ↗
$35M
-
10-K for FY2024, filed Mar 5, 2025
$35M ↗
Who Were Their Customers?
GSK was the company's only customer under the revenue accounting definition. The companies collaborated on developing and commercializing belrestotug.
10-K for FY2024, filed Mar 5, 2025
Did Revenues Turn Into Profits?
No. It lost $134.4M in FY2024.
10-K for FY2024, filed Mar 5, 2025
−$159.5MView ↗
10-K for FY2024, filed Mar 5, 2025
−$134.4MView ↗
10-K for FY2024, filed Mar 5, 2025
−$99.8MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 6, 2025
−$78.7MView ↗
- ▲ +1005% (Loss)
- vs −$7.1M in Q2 FY2024
-
Aug 29, 2025
Concentra completed its acquisition of iTeos
The merger made iTeos a wholly owned subsidiary of Concentra.
Sources
8-K, filed Aug 29, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on August 29, 2025, Parent completed a tender…View ↗
-
Jul 21, 2025
Agreed to be acquired by Concentra Biosciences
The offer included $10.047 in cash per share plus a contingent value right.
Sources
8-K, filed Jul 21, 2025
On July 18, 2025, iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the…View ↗
-
May 28, 2025
Announced plans to wind down clinical and operational activities
The company planned to end its clinical and operating activities while exploring sales of certain assets.
Sources
8-K, filed May 28, 2025
On May 28, 2025, iTeos Therapeutics, Inc. (the “Company”) announced its intention to wind down its clinical and operational activities. The…View ↗
-
May 13, 2025
Ended belrestotug development and the GSK collaboration
The lung study missed its criteria for a meaningful progression-free-survival improvement, and the parties ended the program.
Sources
8-K, filed May 13, 2025
On May 13, 2025, iTeos Belgium S.A., a wholly owned subsidiary of iTeos Therapeutics, Inc. (the “Company”), received written notice from…View ↗
Pipeline focus
The earlier report described inupadenant as an active adenosine-pathway program and planned further trials; the latest report describes a small molecule targeting adenosine transport into immune cells and an antibody targeting tumor macrophages, and says it will not invest further in inupadenant.
10-K for FY2021, filed Mar 23, 2022 10-K for FY2024, filed Mar 5, 2025We are also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated…View ↗
Our second clinical program is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by…View ↗
We are also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes triggering receptor expressed on myeloid…View ↗
In December 2024, we presented clinical, translational, and preclinical data from our adenosine A2AR antagonist program, inupadenant, also…View ↗
Who Did They Compete With?
Competes with AstraZeneca, Gilead, Incyte, Merck, Pfizer, Roche/Genentech, Agenus, Mereo Biopharma Group, Beigene, Arcus, Innovent, Corvus Pharmaceuticals, Riboscience, I-Mab, Oric Pharmaceuticals, Innate Pharma, Akeso, and Trishula Therapeutics
10-K for FY2024, filed Mar 5, 2025We face competition with respect to our current product candidates, and will face competition with respect to future product candidates…View ↗
Loading...
